This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Once considered a passing phase, the concentration of capital into fewer, larger venturecapital deals appears to be the new normal. based venture-backed companies as of the end of the third quarter hit a decade high, and is on pace to pass the $100 billion mark by year’s end. That’s more.
Venturecapital investments rose in 2018 to levels not seen since the heady days of 2000, the last year U.S. That’s according to PitchBook and the National VentureCapital Association’s Venture Monitor report, released this week, which tallied nearly 9,000 deals made last year, through which venture investors sunk $130.9
2018 was a year of ups and downs for the business and technology community. Venture funding remained strong, but more money went to fewer (and later-stage) companies overall. Storylines in various sectors helped shape the overall narrative in 2018. Read more » Reprints | Share: UNDERWRITERS AND PARTNERS.
Venturecapital investors sank $547.2 million into 37 startup companies throughout San Diego County during the first three months of 2018, maintaining roughly the same level of venture funding seen in recent quarters, according to the Venture Monitor Report. It was almost 4 percent higher than the $526.7
Venturecapital firms invest in potentially disruptive technologies with the hope of profit, then keep watch for further advances that could overtake their existing portfolio companies. All this is done while they guide startups through other external challenges such as fundraising droughts and overall market downturns.
View the Slideshow On November 4-6, Xconomy organized a meeting of the minds—an elite gathering of leaders in technology, business, healthcare, education, and energy—to discuss and demonstrate the key trends in their fields, heading into next year.
The sector saw more big venturecapital deals and acquisitions , while researchers kept plugging away on technology advances. software startups to reflect on the trends that defined the sector in 2018—and where things might be headed in 2019. It was an eventful year for the artificial intelligence industry.
venturecapital investments swelled to a level not seen since the dot-com era of the early 2000s. companies through the first six months of 2018, according to the latest Venture Monitor report produced quarterly by Seattle-based PitchBook and the National VentureCapital Association (NVCA). Last year, U.S.
Venturecapital investors poured more than $28.2 companies during the first three months of 2018—marking the strongest single quarter in at least a dozen years, according to the Venture Monitor Report released today by Seattle-based PitchBook and the National VentureCapital Association (NVCA).
Privately held biotech ViaCyte has banked $27 million, the majority an installment of cash from a tranched $80 million Series D financing round it closed in late 2018.
She succeeds Greg McKee, who served as president and CEO of the San Diego-based organization for five years before stepping down last month to start a venturecapital fund. She’s also a partner in Ad Astra Ventures, an accelerator and venture fund for women-led startups she started in 2018 with Allison Long Pettine and Vidya Dinamani.
After a breakout year in 2017, the blockchain sector suffered a series of blows in 2018, from crashing cryptocurrency prices to increased regulatory scrutiny of crypto ventures and deepening skepticism about whether the technology was actually useful.
René Pinnell says he and his wife Selena Pinnell were “blown away” by the virtual reality projects their friends were creating in 2014, so they looked for an entrepreneurial niche that would allow them to support such artists. That year the couple, both trained in design, founded a startup in San Francisco, then called KaleidoscopeVR.
Atomico, a European venturecapital firm, has helped persuade Cambridge, UK-based Healx to return to the capital market a year earlier than anticipated. It is not surprising that venture capitalists have been knocking on the door at Healx. Read more » Reprints | Share:
Xconomy: If you think public perception about the tech industry turned for the worse in 2017, what should the industry do to rebuild trust in 2018? (Palmer previously co-founded Vertica Systems, now part of HP.) Andy Palmer: I think that increased awareness of gender equity issues. Read more » Reprints | Share:
On Monday Erasca—a portmanteau of “erase” and “cancer”— announced it had completed a Series B financing round jointly led by Arch Venture Partners and Cormorant Asset Management. The San Diego-based biotech, which started operations about 18 months ago, made its public debut in December 2018 with $42 million.
This fall, we are convening exemplary business leaders, investors, and far-seeing technologists for an in-depth exploration of the innovation ecosystem and its impact on the future. Come join us at our newest interactive conference, XCON: The Xconomy Conference on Technology and Transformation.
When we have a chance to view it from a distance, the year 2018 may be seen as a period when innovations in a number of technological fields came together to transform not only the future of computing, but also the very structure of the Internet.
With 2018 around the corner, this was a week to look ahead. At Xconomy, we zeroed in on several clinical trials that could become major stories in the life sciences. Other healthcare milestones are on the way, too. The FDA will consider for the first time whether a video game should be approved as medicine.
Station F is led by Roxanne Varza , who’s been very actively supporting startups and the French startup ecosystem as former head of Microsoft Accelerator in France, cofounder of European blog Tech.eu. Amongst its tenants are over 10 VC funds who have taken desks on Campus: Accel, Index Ventures, Balderton, Daphni, Partech Ventures.
The top biopharma story of the week involves the fast-moving field of lung cancer, which, as we’ve written previously, has several key trials reading out in 2018. A big domino fell this week: data from a two-drug immunotherapy combination developed by Bristol-Myers Squibb. But the results, touted as positive, left more questions than answers.
The money came from a wide range of backers, not just traditional biotech venture firms. It’s early yet in 2018, but the current count could put life-sciences companies on pace to bust past last year’s $17.6 billion, a figure compiled in the Venture Monitor Report. Elsewhere, the U.S.
Proceeds will be used to advance Metacrine’s lead drug candidate, MET409, into first-in-human studies during the first half of 2018. Initial studies should be completed by the end of the year, the San Diego-based company said.
Yet in 2018, perceptions about these dominant companies often reflected uneasiness and doubt—and for some, so did their stock performance. The market caps of some of the most successful tech titans reach as high as $1 trillion.
My goal in the interview overall was to capture more of the personal side of Fred since so much of his investment thesis and portfolio work already comes out in his blog. We talk a lot about his schooling, his early jobs as a developer and then as a VC and we talk about his decision to spend winters in Los Angeles.
VC funding. We love capital efficiency until we love land grabs until we abhor over funding until we get huge payouts and ring the bell for more funding until we attract every non-VC on the planet to invest in startups until it crashes and we start the cycle all over again none the wiser. blog here ). April 30th, 2018.
First it was street-style photography, then came the launch of her popular fashion blog WeWoreWhat. Another company, Tribe , has similarly raised VC to grow its American footprint. The firm even launched an accelerator for YouTube personalities in late 2018. With new followers — today her account, @weworewhat , has 2.2
million in seed—in 2018 to advance its growing suite of products, digitized. The team at Trust & Will, a San Diego-based startup founded in October of 2017, is betting that a good chunk of those people would shell out some money to outline an estate plan if the process were cheaper and easier.
But when the financial oversight council published its 2018 annual report, it concluded that volatility in the cryptocurrency. Read more » Reprints | Share: UNDERWRITERS AND PARTNERS.
From Portland to Pittsburgh, it’s likely that every city in the U.S. with more than 1 million people has made its case to Amazon to locate the company’s second headquarters there. At least, hopefully they have already, because today—if you haven’t heard—was the deadline to apply.
In 2018, my Exome colleagues and I published hundreds of stories about health, medicine, the biopharma industry, government policy, and more. You’ll find a few of our favorite stories in this review of some of the year’s best from across the Xconomy network.
Amazon will pick the city in 2018. Amazon sent cities across North America into a frenzy Thursday after announcing plans to build a second headquarters outside of Seattle, bringing with it tens of thousands of jobs and billions of dollars in economic development benefits. Mexico is also part.
billion in 2018, and Novartis reportedly knew but failed to report it to the FDA before the agency approved Zolgensma in May. We learned last week that the FDA was investigating Novartis for manipulating animal data related to its $2 million-a-dose gene therapy Zolgensma. The activity took place at AveXis, the firm Novartis bought for $8.7
As Xconomy’s editors looked back at the year just passed, we asked technology leaders to comment on the trends they’d observed in 2018, and the developments they expected in 2019.
In 2018, geopolitical events—in particular, President Donald Trump’s hard-line stances on trade and immigration, and the repeal of net neutrality rules—were top of mind for several business executives we interviewed recently.
We organize all of the trending information in your field so you don't have to. Join 5,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content